Immune checkpoint inhibition for the treatment of renal cell carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, N., Clinical practice guidelines in oncology. [cited 2016 Jan 18]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf, version 2.2016.
   Google Scholar
• Escudier B, Porta CEA, Schmidinger M, et al. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(supll 3):iii49–iii56.
   PubMedGoogle Scholar
• George DJ, Kaelin WG. The von Hippel–lindau Protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003;349(5):419–421.
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003;14(11):2703–2711.
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith OF, et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma. Cancer. 2008;113(2):293–301.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Frontera OA, Hammers HJ, et al. Thirty-month follow-up of the phase III checkmate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2019;37(7_suppl):547.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Chen H, Girgis K, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Toomey S. et al. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenvironment. 2015;8(1):15–21.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Eruslanov E, Kübler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346–353.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–642.
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.
   PubMed Web of Science ®Google Scholar
• Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008;57(8):1115–1124.
   PubMed Web of Science ®Google Scholar
• Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35(15_suppl):4505.
   Google Scholar
• Bradley CA. Checkpoint inhibitor combination sets the wheels IMmotion. Nat Rev Urol. 2018;15(8):465.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: A randomized phase iii study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6_suppl):578.
   Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Rini BI, Larkin JMG, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: phase 3 study (JAVELIN Renal 101). J Clin Oncol. 2017;35(15_suppl):TPS4594–TPS4594.
   Google Scholar
• Motzer RJ, Penkov K, Haanen JBAG, et al. LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29:suppl_8. p. mdy424.036-mdy424.036
   Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee J-H, Szczylik C, et al., KEYNOTE-427 trial evaluates immunotherapy in advanced clear cell renal cell carcinoma ASCO Annual Meeting 2018. (Abstract 4500).
   Google Scholar
• McDermott DF, Lee J-L, Ziobro M, et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): results from KEYNOTE-427 cohort B. J Clin Oncol. 2019;37(7_suppl):546.
   Web of Science ®Google Scholar
• Moreira RB, McKay RR, Xie W, et al. Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol. 2017;35(6_suppl):482.
   PubMedGoogle Scholar
• McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J Clin Oncol. 2016;34(8):833–842.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Millis SZ, Carballido EM, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3(12):1303–1307.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Goekbuget national library of medicine (us), randomized phase-ii study of nivolumab plus ipilimumab vs. Standard of care in untreated and advanced non-clear cell RCC (SUNIFORECAST). 2017 March 9. [cited 2018 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03075423?id=NCT03075423&rank=1&load=cart
   Google Scholar
• Ljungberg B, Albiges L, Bensalah K, et al., European association of urology guidelines on renal cell carcinoma. Available from: http://uroweb.org/guideline/renal-cell-carcinoma/; 2017.
   Google Scholar
• Büttner F, Winter S, Rausch S, et al. Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. BMC Med. 2018;16(1):108.
   PubMedGoogle Scholar
• Ljungberg B, Albiges L, Bensalah K, et al., European association of urology guidelines on renal cell carcinoma. [cited2018 Aug 25]. Available from: http://uroweb.org/guideline/renal-cell-carcinoma/Accessdate; 2018.
   Google Scholar
• Meissner MA, McCormick BZ, Karam JA, et al. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018;18(7):663–671.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Quinn DI, Zhang T, et al. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. J Clin Oncol. 2018;36(15_suppl):TPS4599-TPS4599.
   Google Scholar
• Uzzo R, Bex A, Rini BI, et al. A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010). J Clin Oncol. 2017;35(15_suppl):TPS4598–TPS4598.
   Google Scholar
• ClinicalTrials.gov Goekbuget national library of medicine (US) national library of medicine (US), nivolumab in treating patients with localized kidney cancer undergoing nephrectomy. [cited 2017 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT03055013?term=prosper&cond=Renal+Cell+Carcinoma&rank=1.
   Google Scholar
• ClinicalTrials.gov. National library of medicine (US), a study comparing the combination of nivolumab and ipilimumab versus placebo in participants with Localized renal cell carcinoma (CheckMate 914). [cited 2017 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03138512.
   Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–2184.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757–1761.
   Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174–17179.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143–148.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162.
   PubMed Web of Science ®Google Scholar
• Brauer MJ, Zhuang G, Schmidt M, et al. Identification and analysis of in vivo vegf downstream markers link VEGF pathway activity with efficacy of Anti-VEGF therapies. Clin Cancer Res. 2013;19(13):3681–3692.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–3385.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704.
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004;101(29):10691–10696.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009–1021.
   PubMed Web of Science ®Google Scholar
• Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013;19(4):324–332.
   PubMed Web of Science ®Google Scholar
• Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78(1):273–304.
   PubMedGoogle Scholar
• Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751.
   PubMed Web of Science ®Google Scholar
• Kapur P, Peña-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14(2):159–167.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19(12):3259–3267.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Chen Y-B, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol. 2013;63(5):848–854.
   PubMed Web of Science ®Google Scholar
• Pawłowski R, Mühl SM, Sulser T, et al. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer. 2013;132(2):E11–E17.
   PubMed Web of Science ®Google Scholar
• Miao D, Margolis C, Martini D, et al. Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. J Clin Oncol. 2017;35(15_suppl):3016.
   Google Scholar
• Voss MH, Kuo F, Chen D, et al. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol. 2017;35(15_suppl):4523.
   Google Scholar
• Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801–806.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Chen D, Wang PI, et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol. 2017;71(3):405–414.
   PubMed Web of Science ®Google Scholar
• Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018;14(9):2178–2182.
   PubMed Web of Science ®Google Scholar
• Kouidhi S, Ben Ayed F, Benammar Elgaaied A. Targeting tumor metabolism: a new challenge to improve immunotherapy. Front Immunol. 2018;9(353).
   PubMedGoogle Scholar
• Lucarelli G, Rutigliano M, Ferro M, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol Oncol. 2017;35(7):461.e15–461.e27.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Loizzo D, Franzin R, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Sallustio F, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging (Albany NY). 2018;10(12):3957–3985.
   PubMedGoogle Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541:321.
   PubMed Web of Science ®Google Scholar